Shares of Evoke plc (LON:EVOK – Get Free Report) were down 10% during mid-day trading on Thursday . The company traded as low as GBX 50.20 ($0.65) and last traded at GBX 51.73 ($0.67). Approximately 65,066,164 shares traded hands during trading, an increase of 1,994% from the average daily volume of 3,107,171 shares. The stock had previously closed at GBX 57.45 ($0.74).
Analysts Set New Price Targets
Several equities analysts recently commented on the stock. Berenberg Bank dropped their price objective on shares of Evoke from GBX 130 ($1.68) to GBX 90 ($1.16) and set a “buy” rating for the company in a research note on Wednesday, December 4th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 140 ($1.81) price target on shares of Evoke in a research note on Monday, December 16th.
Read Our Latest Research Report on EVOK
Evoke Price Performance
Evoke (LON:EVOK – Get Free Report) last posted its earnings results on Wednesday, March 26th. The company reported GBX (6.40) (($0.08)) EPS for the quarter. Evoke had a negative return on equity of 517.98% and a negative net margin of 8.50%. As a group, sell-side analysts forecast that Evoke plc will post 12.7648305 earnings per share for the current year.
Insider Buying and Selling
In related news, insider Andrea Gisle Joosen bought 14,572 shares of the business’s stock in a transaction on Tuesday, January 28th. The shares were purchased at an average cost of GBX 70 ($0.91) per share, with a total value of £10,200.40 ($13,202.69). 27.00% of the stock is currently owned by insiders.
About Evoke
Featured Articles
- Five stocks we like better than Evoke
- What is Put Option Volume?
- MarketBeat Week in Review – 03/24 – 03/28
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- Stock Analyst Ratings and Canadian Analyst Ratings
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Evoke Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke and related companies with MarketBeat.com's FREE daily email newsletter.